advertisement
Abstract #8549 Published in IGR 5-1
Role of transforming growth factor β in conjunctival scarring
Cordeiro MFClinical Science 2003; 104: 181-187
Glaucoma is the major cause of irreversible blindness throughout the world. Of all of the treatments available at present, the most effective appears to be surgery; however, excessive conjunctival scarring can lead to surgical failure. In the last decade, the introduction of the anti-metabolites mitomycin-C and 5-fluorouracil as anti-scarring treatments has greatly improved the results of glaucoma surgery, but these agents are associated with complications that can potentially result in blindness. A possible target for a more physiological approach to anti-scarring is transforming growth factor β. This review examines the role of transforming growth factor β in conjunctival scarring and discusses promising new ways of modifying its activity.
Dr. M.F. Cordeiro, Department of Pathology, Moorfields Eye Hospital, Institute of Ophthalmology, Bath Street, London ECIV 9EL, UK. m.cordeiro@ucl.ac.uk
Classification:
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
